-+ 0.00%
-+ 0.00%
-+ 0.00%

NEXALIN TECHNOLOGY’S Q-SUBMISSION FOR GEN-2 SYNC ACCEPTED BY U.S. FDA FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND DEMENTIA

Reuters·11/05/2025 13:30:15

Please log in to view news